Index RUT
P/E -
EPS (ttm) -2.20
Insider Own 24.24%
Shs Outstand 44.45M
Perf Week 14.05%
Market Cap 2.35B
Forward P/E -
EPS next Y -2.79
Insider Trans -7.53%
Shs Float 41.54M
Perf Month 7.11%
Income -107.85M
PEG -
EPS next Q -0.66
Inst Own 90.10%
Short Float 14.56%
Perf Quarter 19.20%
Sales 0.00M
P/S -
EPS this Y -13.08%
Inst Trans 1.75%
Short Ratio 11.11
Perf Half Y -0.21%
Book/sh 5.98
P/B 7.15
EPS next Y -9.68%
ROA -36.41%
Short Interest 6.05M
Perf Year 161.01%
Cash/sh 7.01
P/C 6.10
EPS next 5Y -
ROE -46.05%
52W Range 9.24 - 50.78
Perf YTD 178.15%
Dividend Est. -
P/FCF -
EPS past 5Y 10.22%
ROI -28.49%
52W High -15.75%
Beta 0.99
Dividend TTM -
Quick Ratio 21.15
Sales past 5Y 0.00%
Gross Margin -
52W Low 362.99%
ATR (14) 2.17
Dividend Ex-Date -
Current Ratio 21.15
EPS Y/Y TTM 33.79%
Oper. Margin 0.00%
RSI (14) 67.58
Volatility 6.66% 5.34%
Employees 51
Debt/Eq 0.16
Sales Y/Y TTM -
Profit Margin -
Recom 1.22
Target Price 61.33
Option/Short Yes / Yes
LT Debt/Eq 0.15
EPS Q/Q -35.24%
Payout -
Rel Volume 2.42
Prev Close 41.99
Sales Surprise -
EPS Surprise -10.71%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 544.09K
Price 42.78
SMA20 11.52%
SMA50 14.56%
SMA200 20.99%
Trades
Volume 1,316,398
Change 1.88%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-25-24 Initiated
Oppenheimer
Outperform
$26
Jan-08-24 Initiated
Cantor Fitzgerald
Overweight
Dec-18-23 Initiated
Raymond James
Outperform
$29
Nov-10-23 Upgrade
Jefferies
Hold → Buy
$18 → $26
Aug-16-23 Initiated
Guggenheim
Buy
$27
Jan-04-23 Downgrade
Wedbush
Outperform → Neutral
$33 → $8
Jan-04-23 Downgrade
Jefferies
Buy → Hold
$32 → $6
Jul-12-22 Initiated
JP Morgan
Overweight
$35
May-02-22 Initiated
H.C. Wainwright
Buy
$35
Apr-19-22 Initiated
Wedbush
Outperform
$32
Sep-16-24 08:00AM
Sep-12-24 08:00AM
Sep-10-24 04:05PM
Sep-05-24 01:07AM
Sep-03-24 08:27AM
08:27AM
Loading…
08:27AM
07:49AM
Sep-02-24 06:05PM
Aug-29-24 08:00AM
Aug-09-24 04:05PM
Aug-08-24 08:00AM
Jul-05-24 04:30PM
Jul-01-24 08:00AM
Jun-11-24 04:01PM
Jun-07-24 04:05PM
04:05PM
Loading…
04:05PM
May-28-24 08:00AM
May-25-24 09:40AM
May-17-24 04:27PM
May-10-24 05:38AM
May-09-24 01:53PM
08:00AM
May-07-24 04:38PM
Apr-23-24 05:09PM
(The Wall Street Journal)
Apr-13-24 05:29AM
Apr-12-24 07:01PM
Apr-11-24 04:29PM
(Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM
Apr-02-24 08:00AM
Mar-20-24 12:52PM
07:30AM
Loading…
07:30AM
Feb-28-24 04:20PM
Feb-02-24 12:40PM
08:00AM
Feb-01-24 04:05PM
Jan-29-24 11:50PM
06:15AM
Jan-25-24 06:30AM
Jan-12-24 06:44PM
Jan-08-24 08:01AM
08:00AM
Dec-27-23 08:00AM
Dec-15-23 10:15AM
Nov-14-23 05:05PM
09:55AM
Nov-09-23 09:29AM
08:00AM
Nov-04-23 10:00AM
Oct-30-23 08:00AM
Oct-18-23 09:35AM
Oct-17-23 09:35AM
Oct-16-23 09:35AM
Oct-13-23 10:22AM
Sep-26-23 04:02PM
Aug-31-23 08:00AM
Aug-16-23 10:00AM
Aug-15-23 04:03PM
Aug-10-23 08:00AM
Aug-04-23 06:30PM
Jul-24-23 09:01AM
Jul-07-23 06:35PM
Jun-27-23 08:05AM
Jun-20-23 07:04PM
09:33AM
Jun-17-23 10:10AM
Jun-15-23 04:44PM
Jun-12-23 12:05PM
Jun-11-23 01:08PM
Jun-08-23 08:00AM
Jun-07-23 08:00AM
May-11-23 08:36AM
07:30AM
May-04-23 08:00AM
Mar-28-23 07:30AM
Feb-27-23 04:05PM
Feb-14-23 07:48AM
Feb-09-23 06:51AM
05:54AM
Feb-06-23 04:05PM
Feb-01-23 09:52PM
04:01PM
Jan-30-23 07:35AM
06:00AM
Jan-25-23 08:00AM
Jan-22-23 07:39AM
Jan-06-23 05:02AM
Jan-04-23 04:07PM
(Investor's Business Daily) -64.70%
-13.31%
12:20PM
10:22AM
06:52AM
Jan-03-23 04:01PM
Dec-20-22 04:05PM
Nov-25-22 07:38AM
Nov-22-22 07:30AM
Nov-17-22 07:30AM
Nov-09-22 07:30AM
Nov-05-22 04:50PM
Oct-17-22 07:30AM
Sep-15-22 09:55AM
Sep-07-22 07:30AM
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SEIDENBERG BETH C Director Sep 19 '24 Sale 42.31 13,823 584,793 146,553 Sep 20 04:45 PM SEIDENBERG BETH C Director Sep 18 '24 Sale 42.00 1,476 61,992 4,012 Sep 20 04:45 PM SEIDENBERG BETH C Director Sep 18 '24 Sale 42.01 1,177 49,448 160,376 Sep 20 04:45 PM BETH C SEIDENBERG Director Sep 18 '24 Proposed Sale 40.02 15,000 600,300 Sep 18 04:38 PM SAMUEL B SEIDENBERG IRREV TRUS Director Sep 18 '24 Proposed Sale 40.02 1,476 59,070 Sep 18 04:38 PM Fordyce Marshall PRESIDENT AND CEO Sep 11 '24 Option Exercise 2.90 15,625 45,262 317,246 Sep 13 04:36 PM Fordyce Marshall PRESIDENT AND CEO Sep 11 '24 Sale 37.50 15,625 585,934 307,972 Sep 13 04:36 PM MARSHALL FORDYCE Director Sep 11 '24 Proposed Sale 37.55 31,250 1,173,438 Sep 11 04:19 PM Fordyce Marshall PRESIDENT AND CEO Aug 28 '24 Option Exercise 2.90 15,625 45,262 337,592 Aug 30 04:04 PM Fordyce Marshall PRESIDENT AND CEO Aug 28 '24 Sale 36.84 30,320 1,117,140 307,972 Aug 30 04:04 PM MARSHALL FORDYCE Director Aug 28 '24 Proposed Sale 37.65 30,320 1,141,548 Aug 28 04:15 PM Fordyce Marshall PRESIDENT AND CEO Aug 21 '24 Sale 39.76 14,471 575,425 322,667 Aug 23 05:40 PM Fordyce Marshall PRESIDENT AND CEO Aug 14 '24 Option Exercise 2.90 15,625 45,262 352,763 Aug 16 04:31 PM Fordyce Marshall PRESIDENT AND CEO Aug 14 '24 Sale 37.56 15,625 586,927 337,138 Aug 16 04:31 PM MARSHALL FORDYCE Director Aug 14 '24 Proposed Sale 37.95 15,625 592,969 Aug 14 04:24 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 16 '24 Option Exercise 7.87 20,651 162,523 69,357 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 15 '24 Option Exercise 3.94 8,221 32,387 61,392 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 16 '24 Sale 42.32 20,651 873,890 51,206 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 15 '24 Sale 42.27 10,186 430,546 51,206 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR Apr 10 '24 Sale 40.00 5,714 228,560 53,171 Apr 12 04:02 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Option Exercise 14.87 99,828 1,484,442 166,165 Apr 05 09:32 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 39.61 99,828 3,954,516 66,337 Apr 05 09:32 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 39.42 18,649 735,205 0 Apr 05 09:32 PM Katabi Maha Director Mar 22 '24 Sale 40.51 413,450 16,748,860 3,133,987 Mar 25 09:46 PM Katabi Maha Director Mar 25 '24 Sale 40.50 340,000 13,770,000 2,793,987 Mar 25 09:46 PM Katabi Maha Director Mar 21 '24 Sale 44.20 81,009 3,580,723 3,547,437 Mar 25 09:46 PM Katabi Maha Director Jan 30 '24 Buy 31.00 161,290 4,999,990 3,628,446 Feb 01 05:58 PM COMMODORE CAPITAL LP 10% Owner Jan 10 '24 Sale 18.00 1,050,000 18,900,000 4,400,000 Jan 12 09:55 PM Fordyce Marshall President and CEO Dec 29 '23 Option Exercise 2.87 13,516 38,854 256,877 Jan 03 04:15 PM
Index -
P/E -
EPS (ttm) -1.14
Insider Own 34.36%
Shs Outstand 21.38M
Perf Week -15.59%
Market Cap 101.11M
Forward P/E -
EPS next Y -3.43
Insider Trans -0.40%
Shs Float 21.13M
Perf Month 1.95%
Income -29.25M
PEG -
EPS next Q -0.39
Inst Own 53.34%
Short Float 8.79%
Perf Quarter -20.10%
Sales 2.00M
P/S 50.55
EPS this Y 44.74%
Inst Trans -
Short Ratio 4.46
Perf Half Y -32.47%
Book/sh 5.74
P/B 0.55
EPS next Y -133.33%
ROA -27.79%
Short Interest 1.86M
Perf Year -72.93%
Cash/sh 5.17
P/C 0.61
EPS next 5Y -
ROE -29.32%
52W Range 2.13 - 20.71
Perf YTD -42.07%
Dividend Est. -
P/FCF -
EPS past 5Y -16.23%
ROI -15.96%
52W High -84.84%
Beta 3.61
Dividend TTM -
Quick Ratio 29.11
Sales past 5Y 0.00%
Gross Margin 98.25%
52W Low 47.42%
ATR (14) 0.34
Dividend Ex-Date -
Current Ratio 29.11
EPS Y/Y TTM -
Oper. Margin -1813.75%
RSI (14) 48.63
Volatility 10.62% 10.44%
Employees 10
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -1462.55%
Recom 1.33
Target Price 32.60
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 19.85%
Payout -
Rel Volume 1.09
Prev Close 3.28
Sales Surprise -
EPS Surprise 24.63%
Sales Q/Q -
Earnings Aug 14 BMO
Avg Volume 415.87K
Price 3.14
SMA20 -0.93%
SMA50 0.68%
SMA200 -37.29%
Trades
Volume 455,257
Change -4.27%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-28-24 Downgrade
Goldman
Buy → Neutral
$23 → $6
May-02-24 Initiated
H.C. Wainwright
Buy
$32
Mar-25-24 Initiated
Leerink Partners
Outperform
$26
Aug-08-23 Initiated
TD Cowen
Outperform
Aug-08-23 Initiated
Piper Sandler
Overweight
$67
Aug-08-23 Initiated
JMP Securities
Mkt Outperform
$30
Aug-08-23 Initiated
Goldman
Buy
$33
Sep-12-24 07:30AM
Sep-04-24 08:00AM
Aug-14-24 08:00AM
Aug-01-24 08:00AM
Jun-10-24 08:00AM
05:00AM
Loading…
Jun-06-24 05:00AM
May-16-24 08:00AM
May-15-24 12:53PM
08:00AM
May-07-24 08:00AM
May-06-24 08:00AM
Apr-22-24 08:00AM
Mar-27-24 04:01PM
(GlobeNewswire) +9.56%
-5.41%
Mar-25-24 07:00AM
06:15AM
08:00AM
Loading…
Feb-29-24 08:00AM
Jan-25-24 08:58PM
(GlobeNewswire) -13.62%
-23.89%
Jan-23-24 05:45PM
Jan-22-24 11:10PM
07:00AM
Dec-04-23 08:00AM
Nov-28-23 08:00AM
Nov-22-23 08:00AM
Nov-13-23 08:00AM
Nov-10-23 08:30AM
Oct-24-23 11:00AM
Oct-18-23 04:05PM
Sep-27-23 04:05PM
Aug-29-23 10:21AM
Aug-21-23 04:02PM
04:04PM
Loading…
Aug-15-23 04:04PM
Aug-08-23 10:02AM
Jul-20-23 04:05PM
Jul-13-23 09:10PM
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kemble George Executive Chairman Jul 23 '24 Sale 3.17 23,625 74,830 118,693 Jul 25 04:05 PM Martins Eduardo Bruno Chief Medical Officer Jul 19 '24 Sale 3.10 8,357 25,910 81,213 Jul 23 04:06 PM Rozek Elizabeth General Counsel and CCO Jul 19 '24 Sale 3.10 10,914 33,830 160,506 Jul 23 04:05 PM Kemble George Executive Chairman Jul 19 '24 Sale 3.10 14,062 43,605 142,318 Jul 23 04:05 PM Happel David President & CEO Mar 26 '24 Buy 5.27 12,100 63,731 639,200 Mar 28 04:08 PM Happel David President & CEO Dec 07 '23 Buy 4.10 1,600 6,560 627,100 Dec 08 04:05 PM Happel David President & CEO Nov 16 '23 Buy 2.35 590 1,386 590 Nov 20 09:59 PM
Index RUT
P/E -
EPS (ttm) -3.06
Insider Own 35.41%
Shs Outstand 97.87M
Perf Week 14.68%
Market Cap 537.98M
Forward P/E -
EPS next Y -2.10
Insider Trans -0.03%
Shs Float 64.46M
Perf Month 12.29%
Income -299.80M
PEG -
EPS next Q -0.80
Inst Own 77.37%
Short Float 11.16%
Perf Quarter 32.11%
Sales 0.00M
P/S -
EPS this Y 45.60%
Inst Trans -
Short Ratio 6.28
Perf Half Y -30.72%
Book/sh 5.71
P/B 0.94
EPS next Y 28.97%
ROA -40.33%
Short Interest 7.20M
Perf Year -45.28%
Cash/sh 6.36
P/C 0.85
EPS next 5Y -
ROE -43.79%
52W Range 3.36 - 10.70
Perf YTD -27.75%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -52.66%
52W High -49.65%
Beta 2.29
Dividend TTM -
Quick Ratio 7.86
Sales past 5Y 0.00%
Gross Margin -
52W Low 60.42%
ATR (14) 0.44
Dividend Ex-Date -
Current Ratio 7.86
EPS Y/Y TTM -
Oper. Margin 0.00%
RSI (14) 59.10
Volatility 10.31% 8.17%
Employees 130
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.86
Target Price 11.40
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -222.51%
Payout -
Rel Volume 2.85
Prev Close 5.30
Sales Surprise -
EPS Surprise -10.26%
Sales Q/Q -
Earnings Aug 13 AMC
Avg Volume 1.15M
Price 5.39
SMA20 14.01%
SMA50 2.02%
SMA200 -9.42%
Trades
Volume 3,268,593
Change 1.70%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-24 Downgrade
H.C. Wainwright
Buy → Neutral
$18 → $6
Jul-08-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$13
Dec-13-23 Initiated
Wells Fargo
Equal Weight
$11
Dec-08-23 Initiated
Citigroup
Neutral
$8
Sep-13-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$19
Sep-05-23 Initiated
H.C. Wainwright
Buy
$44
May-30-23 Initiated
TD Cowen
Outperform
May-30-23 Initiated
Piper Sandler
Overweight
$68
May-30-23 Initiated
Morgan Stanley
Overweight
May-30-23 Initiated
Jefferies
Buy
$31
Sep-19-24 07:00AM
Sep-12-24 01:30AM
Sep-10-24 07:00AM
Aug-22-24 07:00AM
Aug-13-24 04:00PM
03:37AM
Loading…
03:37AM
Aug-06-24 04:30PM
Jun-05-24 07:00AM
May-29-24 07:00AM
May-15-24 11:54AM
May-09-24 08:01AM
08:00AM
Apr-29-24 04:05PM
Mar-28-24 10:53PM
04:05PM
04:01PM
Loading…
Mar-27-24 04:01PM
Mar-21-24 11:12AM
Mar-20-24 07:00AM
12:39AM
Mar-11-24 10:04AM
(FierceBiotech.com) +10.96%
08:02AM
08:00AM
Feb-15-24 04:05PM
Jan-10-24 11:30AM
Jan-04-24 09:56AM
Jan-01-24 09:35AM
Dec-27-23 10:45AM
Dec-20-23 04:30PM
Dec-19-23 12:13AM
Dec-18-23 04:14PM
09:25PM
Loading…
Dec-12-23 09:25PM
Dec-11-23 09:35AM
Dec-04-23 03:00PM
08:00AM
Nov-30-23 04:30PM
Nov-28-23 05:55PM
(GlobeNewswire) -32.41%
+8.16%
01:44PM
07:24AM
Nov-27-23 09:09PM
04:30PM
Nov-20-23 11:01AM
Nov-16-23 06:42PM
04:11PM
Nov-07-23 05:11PM
04:05PM
Nov-06-23 07:00AM
Oct-31-23 04:30PM
Oct-18-23 09:00PM
Oct-03-23 07:00AM
Sep-15-23 05:39PM
Sep-11-23 04:05PM
Sep-06-23 07:00AM
Aug-15-23 07:22PM
Aug-14-23 04:05PM
Aug-07-23 04:30PM
Jul-18-23 07:00AM
Jun-15-23 04:05PM
May-09-23 04:10PM
May-05-23 07:08PM
(The Wall Street Journal)
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Becker Daniel J. Director Jul 17 '24 Sale 6.86 1 7 2,999 Jul 19 06:18 PM Lin Shao-Lee Chief Executive Officer Apr 01 '24 Sale 6.63 9,961 66,024 1,577,374 Apr 03 06:18 PM Lin Shao-Lee Chief Executive Officer Feb 20 '24 Sale 7.60 15,701 119,403 1,587,335 Feb 22 07:04 PM Lin Shao-Lee Chief Executive Officer Jan 02 '24 Sale 7.41 10,691 79,188 1,603,036 Jan 04 06:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite